Medical Virology of Hepatitis B: How it began and where we are now

Virology Journal

Volumn 10, Issue , 2013, Pages

  Gerlich, Wolfram H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Anti HBc; Anti HBs; HBsAg; HCC; Hepadnavirus; Hepatitis B virus; Vaccine

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; LAMIVUDINE; PLACEBO; RECOMBINANT VACCINE; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; VIRUS ANTIBODY; VIRUS DNA; VIRUS RECEPTOR; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ACUTE HEPATITIS; ASSAY; AVIHEPADNAVIRUS; BLOOD DONOR; CARCINOGENICITY; CELL CULTURE; CHEMICAL LABELING; CHRONIC HEPATITIS; CLONING; DNA REPLICATION; ELECTRON MICROSCOPY; EXPERIMENTAL MODEL; GENETIC MARKER; GENOTYPE; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INOCULATION; LIFE CYCLE; MONITORING; MUTAGENESIS; NEPHROTOXICITY; NONHUMAN; ORTHOHEPADNAVIRUS; PASSIVE IMMUNIZATION; PATHOGENICITY; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION; REVIEW; SCREENING; SEROLOGY; SOLID PHASE SANDWICH ASSAY; UNSPECIFIED SIDE EFFECT; VACCINATION; VIREMIA; VIROLOGY; VIRUS CARRIER; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS PARTICLE; VIRUS TRANSMISSION;

CARRIER STATE; CLINICAL LABORATORY TECHNIQUES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS;

HEPADNAVIRIDAE; HEPATITIS B VIRUS;

EID: 84880334408     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-239     Document Type: Review

References (132)

1. Blumberg BS, Hepatitis B-The hunt for a killer virus Princeton: Princeton University Press 2002
2. Lürmann A, Eine Icterusepidemie. Ber Klin Wochenschr 1885 22 20 23
3. 1971 International symposium on viral hepatitis. Historical perspectives. MacCallum FO, Can Med Assoc J 1972 106 Suppl 423 426 4552628
4. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, Kaplowitz N, Koff RS, Petrini JL Jr, Schiff ER, et al. N Engl J Med. 1987 316 965 970 10.1056/NEJM198704163161601 2436048 (Pubitemid 17047919)
5. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Barker LF, Murray R, Am J Med Sci 1972 263 27 33 10.1097/00000441-197201000-00005 5057849
6. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. Krugman S, Giles JP, Hammond J, JAMA 1967 200 365 373 10.1001/jama.1967.03120180053006 4164595
7. Relation of Australia and SH antigens. Prince AM, Lancet 1968 2 7565 462 463 4174193
8. Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125 I-antibody. Ling CM, Overby LR, J Immunol 1972 109 834 841 4627513
9. Subtypes of Australia antigen and hepatitis-B virus. Le Bouvier GL, McCollum RW, Hierholzer WJ Jr, Irwin GR, Krugman S, Giles JP, JAMA 1972 222 928 930 10.1001/jama.1972.03210080020005 4120331
10. Detection of additional antigenic determinants of hepatitis B antigen. Bancroft WH, Mundon FK, Russell PK, J Immunol 1972 109 842 848 4116360
11. Australia antigen (a hepatitis-associated antigen): purification and physical properties. Millman I, Loeb LA, Bayer ME, Blumberg BS, J Exp Med 1970 131 1190 1199 10.1084/jem.131.6.1190 4246140
12. Hepatitis-associated antigen: purification and properties. Gerlich W, May G, Zentralbl Bakteriol Orig A 1973 224 49 60 German 4147404
13. Self-replication and scrapie. Griffith JS, Nature 1967 215 1043 1044 10.1038/2151043a0 4964084
14. Virus-like particles in serum of patients with Australia-antigen- associated hepatitis. Dane DS, Cameron CH, Briggs M, Lancet 1970 1 7649 695 698 4190997
15. New antigen-antibody system in Australia-antigen-positive hepatitis. Almeida JD, Rubenstein D, Stott EJ, Lancet 1971 2 7736 1225 1227 4143591
16. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. Seitz S, Urban S, Antoni C, Böttcher B, EMBO J 2007 26 4160 4167 10.1038/sj.emboj.7601841 17762862 (Pubitemid 47462100)
17. D.N.A. polymerase in preparations containing Australia antigen. Hirschman SZ, Vernace SJ, Schaffner F, Lancet 1971 1 7709 1099 1103 4102625
18. DNA polymerase associated with human hepatitis B antigen. Kaplan PM, Greenman RL, Gerin JL, Purcell RH, Robinson WS, J Virol 1973 12 995 1005 4765400
19. DNA of a human hepatitis B virus candidate. Robinson WS, Clayton DA, Greenman RL, J Virol 1974 14 384 391 4847328
20. Summary statement of the Asilomar conference on recombinant DNA molecules. Berg P, Baltimore D, Brenner S, Roblin RO, Singer MF, Proc Natl Acad Sci USA 1975 72 1981 1984 10.1073/pnas.72.6.1981 806076
21. Cloning in Escherichia coli and physical structure of hepatitis B virion DNA. Charnay P, Pourcel C, Louise A, Fritsch A, Tiollais P, Proc Natl Acad Sci USA 1979 76 2222 2226 10.1073/pnas.76.5.2222 377294 (Pubitemid 9184909)
22. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman HM, Rutter WJ, Nature 1979 280 815 819 10.1038/280815a0 471053 (Pubitemid 9254040)
23. Hepatitis B virus genes and their expression in E. coli. Pasek M, Goto T, Gilbert W, Zink B, Schaller H, MacKay P, Leadbetter G, Murray K, Nature 1979 282 575 579 10.1038/282575a0 399329 (Pubitemid 10213912)
24. Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Wittkop L, Schwarz A, Cassany A, Grün-Bernhard S, Delaleau M, Rabe B, Cazenave C, Gerlich W, Glebe D, Kann M, Cell Microbiol 2010 12 962 975 10.1111/j.1462-5822.2010.01444.x 20109160
25. Cloned HBV DNA causes hepatitis in chimpanzees. Will H, Cattaneo R, Koch HG, Darai G, Schaller H, Schellekens H, van Eerd PM, Deinhardt F, Nature 1982 299 740 742 10.1038/299740a0 7121604 (Pubitemid 12037761)
26. Antibody to hepatitis-B-virus core in man. Hoofnagle JH, Gerety RJ, Barker LF, Lancet 1973 2 7834 869 873 4126916
27. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ, N Engl J Med 1978 298 1379 1383 10.1056/NEJM197806222982502 652005 (Pubitemid 8358627)
28. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Lancet 1975 2 7934 528 530 51345
29. A solid-phase radioimmunoassay for detection of IgM antibodies to hepatitis A virus. Flehmig B, Ranke M, Berthold H, Gerth HJ, J Infect Dis 1979 140 169 175 10.1093/infdis/140.2.169 225390 (Pubitemid 10243087)
30. Selective detection of IgM-antibody against core antigen of the hepatitis B virus by a modified enzyme immune assay. Gerlich WH, Lüer W, J Med Virol 1979 4 227 238 10.1002/jmv.1890040308 395275 (Pubitemid 10206693)
31. Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. Gerlich WH, Uy A, Lambrecht F, Thomssen R, J Clin Microbiol 1986 24 288 293 3745425 (Pubitemid 16061022)
32. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Milich DR, McLachlan A, Science 1986 234 1398 1401 10.1126/science.3491425 3491425 (Pubitemid 17210220)
33. A new antigen complex co-occurring with Australia antigen. Magnius LO, Espmark A, Acta Pathol Microbiol Scand B Microbiol Immunol 1972 80 335 337 4624538
34. A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Standring DN, Ou JH, Masiarz FR, Rutter WJ, Proc Natl Acad Sci USA 1988 85 8405 8409 10.1073/pnas.85.22.8405 3186731 (Pubitemid 19024984)
35. Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein. Bruss V, Gerlich WH, Virology 1988 163 268 275 10.1016/0042-6822(88)90266-8 3354197
36. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC, Lancet 1989 2 8663 588 591 2570285 (Pubitemid 19216208)
37. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. Milich DR, Chen MK, Hughes JL, Jones JE, J Immunol 1998 160 2013 2021 9469465 (Pubitemid 28106492)
38. Experimental infection of chimpanzees with the virus of hepatitis B. Maynard JE, Berquist KR, Krushak DH, Purcell RH, Nature 1972 237 514 515 10.1038/237514a0 12635203
39. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Petersen J, Dandri M, Gupta S, Rogler CE, Proc Natl Acad Sci USA 1998 95 310 315 10.1073/pnas.95.1.310 9419372 (Pubitemid 28103950)
40. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsäcker F, J Virol 2001 75 5084 5089 10.1128/JVI.75.11. 5084-5089.2001 11333889 (Pubitemid 32448530)
41. Mapping of the hepatitis B virus attachment site by infection-inhibiting preS1 lipopeptides using Tupaia hepatocytes. Glebe D, Urban S, Knoop EV, Çag N, Krass P, Grün S, Bulavaite A, Sasnauskas K, Gerlich WH, Gastroenterology 2005 129 234 245 10.1053/j.gastro.2005.03.090 16012950 (Pubitemid 41002057)
42. Infection of a human hepatoma cell line by hepatitis B virus. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C, Proc Natl Acad Sci USA 2002 99 15655 15660 10.1073/pnas.232137699 12432097 (Pubitemid 35403987)
43. Reliability of methods for hepatitis B virus DNA detection. Quint WG, Heijtink RA, Schirm J, Gerlich WH, Niesters HG, J Clin Microbiol 1995 33 225 228 7699047 (Pubitemid 24382434)
44. Hepatitis B virus contains protein attached to the 5' terminus of its complete DNA strand. Gerlich WH, Robinson WS, Cell 1980 21 801 809 10.1016/0092-8674(80)90443-2 7438207 (Pubitemid 10022888)
45. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, WHO Collaborative Study Group, Vox Sang 2001 80 63 71 10.1046/j.1423-0410.2001.00003.x 11339072 (Pubitemid 35333911)
46. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H, J Med Virol 2008 80 2064 2068 10.1002/jmv.21320 19040280
47. Infectivity of blood products from donors with occult hepatitis B virus infection. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M, Transfusion 2013 doi: 10.1111/trf.12096. [Epub ahead of print]
48. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D, Connell J, Gerlich WH, Marinho RT, Tsantoulas D, Rigopoulou E, Rosenheim M, Valla D, Puro V, Struwe J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF, European Consensus Group, J Clin Virol 2003 27 213 230 10.1016/S1386-6532(03)00087-8 12878084 (Pubitemid 36870896)
49. Further data on HBs antigen subtypes-geographical distribution. Couroucé-Pauty AM, Soulier JP, Vox Sang 1974 27 533 549 10.1111/j.1423-0410.1974.tb02451.x 4141815
50. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M, J Gen Virol 1988 69 2575 2583 10.1099/0022-1317-69-10-2575 3171552
51. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO, Intervirology 2004 47 289 309 10.1159/000080872 15564741 (Pubitemid 39541275)
52. Slave trade and hepatitis B virus genotypes and subgenotypes in Haiti and Africa. Andernach IE, Nolte C, Pape JW, Muller CP, Emerg Infect Dis 2009 15 1222 1228 10.3201/eid1508.081642 19751583
53. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. Kramvis A, Kew MC, Hepatol Res 2007 37 Suppl 1 27 S32 17627631
54. The molecular epidemiology of Hepatitis B in the Indigenous people of northern Australia. Davies J, Littlejohn M, Locarnini SA, Whiting S, Hajkowicz K, Cowie BC, Bowden DS, Tong SY, Davis JS, J Gastroenterol Hepatol 2013 [Epub ahead of print] 10.1111/jgh.12177
55. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A, Hepatology 2013 57 908 916 10.1002/hep.26079 22987324
56. Subgenotyping of genotype C hepatitis B virus: correcting misclassifications and identifying a novel subgenotype. Shi W, Zhu C, Zheng W, Zheng W, Ling C, et al. PLoS ONE 2012 7 10 47271 10.1371/journal.pone.0047271 23077582
57. Mason WS, Gerlich WH, Taylor JM, Kann M, Loeb D, Sureau S, Magnius L, Norder H, Family Hepadnaviridae Amsterdam: Elsevier Virus taxonomy, ninth report of the international committee on taxonomy of viruses. 2012 445 455
58. Isolation of a hepadnavirus from the woolly monkey, a new world primate. Lanford RE, Chavez D, Brasky KM, Burns RB 3rd, Rico-Hesse R, Proc Natl Acad Sci USA 1998 95 5757 5761 10.1073/pnas.95.10.5757 9576957 (Pubitemid 28224169)
59. Outbreak of hepatitis B in a nursing home associated with capillary blood sampling. Dreesman JM, Baillot A, Hamschmidt L, Monazahian M, Wend UC, Gerlich WH, Epidemiol. Infect 2006 26 1102 1113 (Pubitemid 44336388)
60. Immunobiology and pathogenesis of viral hepatitis. Guidotti LG, Chisari FV, Annu Rev Pathol. 2006 1 23 61 10.1146/annurev.pathol.1.110304.100230 18039107
61. Statements from the Taormina expert meeting on occult hepatitis B virus infection. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F, J Hepatol 2008 49 652 657 10.1016/j.jhep.2008.07.014 18715666
62. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Westhoff TH, Jochimsen F, Schmittel A, Stöffler-Meilicke M, Schäfer JH, Zidek W, Gerlich WH, Thiel E, Blood 1930 2003 102
63. Reactivation of hepatitis B virus with mutated HBsAg in a liver transplant recipient receiving a graft from an anti-HBs and anti-HBc positive donor. Blaich A, Manz M, Dumoulin A, Schüttler CG, Hirsch HH, Gerlich WH, Frei R, Transfusion 2012 52 1999 2006 10.1111/j.1537-2995.2011.03537.x 22313146
64. Inhibition of hepatitis B virus replication by APOBEC3G. Turelli P, Mangeat B, Jost S, Vianin S, Trono D, Science 2004 303 1829 10.1126/science. 1092066 15031497 (Pubitemid 38374868)
65. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Szmuness W, Prog Med Virol 1978 24 40 69 212785
66. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Beasley RP, Hwang LY, Lin CC, Chien CS, Lancet 1981 2 8256 1129 1133 6118576
67. Establishment of a continuously growing cell line from primary carcinoma of the liver. Alexander JJ, Bey EM, Geddes EW, Lecatsas G, S Afr Med J 1976 50 2124 2128 63998 (Pubitemid 8004296)
68. Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Edman JC, Gray P, Valenzuela P, Rall LB, Rutter WJ, Nature 1980 286 535 538 10.1038/286535a0 6250075 (Pubitemid 10017699)
69. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Kekulé AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R, Nature 1990 343 457 461 10.1038/343457a0 2153938 (Pubitemid 20065231)
70. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. Höhne M, Schaefer S, Seifer M, Feitelson MA, Paul D, Gerlich WH, EMBO Journal 1990 9 1137 1145 2323335
71. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz O, Protzer U, J Hepatol 2011 55 996 1003 10.1016/j.jhep.2011.02.015 21376091
72. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Dejean A, Bougueleret L, Grzeschik KH, Tiollais P, Nature 1986 322 70 72 10.1038/322070a0 3014347 (Pubitemid 16061510)
73. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. Mason WS, Liu C, Aldrich CE, Litwin S, Yeh MM, J Virol 2010 84 8308 8315 10.1128/JVI.00833-10 20519397
74. REVEAL-HBV Study Group: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, JAMA 2006 295 65 73 10.1001/jama.295.1.65 16391218 (Pubitemid 43042691)
75. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Summers J, Smolec JM, Snyder R, Proc Natl Acad Sci USA 1978 75 4533 4537 10.1073/pnas.75.9.4533 212758 (Pubitemid 9028391)
76. A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Marion PL, Oshiro LS, Regnery DC, Scullard GH, Robinson WS, Proc Natl Acad Sci USA 1980 77 2941 2945 10.1073/pnas.77.5.2941 6930677 (Pubitemid 10049853)
77. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Fourel G, Trepo C, Bougueleret L, Henglein B, Ponzetto A, Tiollais P, Buendia MA, Nature 1990 347 294 298 10.1038/347294a0 2205804 (Pubitemid 20284060)
78. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. Mason WS, Seal G, Summers J, J Virol 1980 36 829 836 7463557 (Pubitemid 11194322)
79. Isolation and characterization of a hepatitis B virus endemic in herons. Sprengel R, Kaleta EF, Will H, J Virol 1988 62 3832 3839 3418788
80. The genome of a mesozoic paleovirus reveals the evolution of hepatitis B viruses. Suh A, Brosius J, Schmitz J, Kriegs JO, Nature Communications 2013 4 1791 23653203
81. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Summers J, Mason WS, Cell 1982 29 403 415 10.1016/0092-8674(82)90157-X 6180831 (Pubitemid 12024833)
82. Hepatitis B viruses: reverse transcription a different way. Nassal M, Virus Res 2008 134 235 249 10.1016/j.virusres.2007.12.024 18339439
83. Nuclear import of hepatitis B virus capsids and release of the viral genome. Rabe B, Vlachou A, Panté N, Helenius A, Kann M, Proc Natl Acad Sci USA 2003 100 9849 9854 10.1073/pnas.1730940100 12909718 (Pubitemid 37087030)
84. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. Gerelsaikhan T, Tavis JE, Bruss V, J Virol 1996 70 4269 4274 8676448 (Pubitemid 26187427)
85. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. Bruss V, Lu X, Thomssen R, Gerlich WH, EMBO J 1994 13 2273 2279 8194518 (Pubitemid 24157601)
86. Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. Lambert C, Döring T, Prange R, J Virol 2007 81 9050 9060 10.1128/JVI.00479-07 17553870 (Pubitemid 47311448)
87. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Sells MA, Chen ML, Acs G, Proc Natl Acad Sci USA 1987 84 1005 1009 10.1073/pnas.84.4.1005 3029758 (Pubitemid 17031557)
88. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. Zahn P, Allain JP, J Gen Virol 2005 86 677 685 10.1099/vir.0.80614-0 15722528 (Pubitemid 40331248)
89. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Sureau C, Salisse J, Hepatology 2013 57 985 994 10.1002/hep.26125 23161433
90. Large surface proteins of hepatitis B virus containing the pre-s sequence. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH, J Virol 1984 52 396 402 6492255 (Pubitemid 15202474)
91. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Neurath AR, Kent SB, Strick N, Parker K, Cell 1986 46 429 436 10.1016/0092-8674(86)90663-X 3015414 (Pubitemid 16031679)
92. The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses. Ishikawa T, Ganem D, Proc Natl Acad Sci USA 1995 92 6259 6263 10.1073/pnas.92.14.6259 7603980
93. Gp180, a protein that binds duck hepatitis B virus particles, has metallocarboxypeptidase D-like enzymatic activity. Eng FJ, Novikova EG, Kuroki K, Ganem D, Fricker LD, J Biol Chem 1998 273 8382 8388 10.1074/jbc.273.14.8382 9525948 (Pubitemid 28168899)
94. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH, J Virol 2003 77 9511 9521 10.1128/JVI.77.17.9511-9521.2003 12915565 (Pubitemid 37011046)
95. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W, Elife 2012 1 00049 10.7554/eLife.00049 23150796
96. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC, N Engl J Med 1976 295 517 522 10.1056/NEJM197609022951001 950957
97. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Petersen J, Buti M, Expert Rev Gastroenterol Hepato. 2012 6 683 693 10.1586/egh.12.52
98. Prognostic significance of quantitative HBsAg determination in acute hepatitis B. Partial report of a cooperative clinical study of the DFG-focus of "virus hepatitis" Gerlich W, Stamm B, Thomssen R, Verh Dtsch Ges Inn Med 1977 83 554 557 German 612029
99. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC, Proc Natl Acad Sci USA 1991 88 8495 8499 10.1073/pnas.88.19.8495 1656445 (Pubitemid 21915383)
100. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M, Lancet 1995 345 8946 396 397 10.1016/S0140-6736(95)90388-7 7845151
101. A preliminary trial of lamivudine for chronic hepatitis B infection. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M, N Engl J Med 1995 333 1657 1661 10.1056/NEJM199512213332501 7477217 (Pubitemid 26001954)
102. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Torresi J, Locarnini S, Gastroenterology 2000 118 Suppl 1 83 S103 10868900
103. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Warner N, Locarnini S, Hepatology 2008 48 88 98 10.1002/hep.22295 18537180 (Pubitemid 351975534)
104. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T, Hepatology 2004 40 1421 1425 10.1002/hep.20464 15565615 (Pubitemid 39657017)
105. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX, J Hepatol 2011 55 1215 1221 10.1016/j.jhep.2011.02.032 21703206
106. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Volz T, Allweiss L, Barek MB M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M, J Hepatol 2013 58 861 867 10.1016/j.jhep.2012.12.008 23246506
107. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M, PLoS Pathog 2013 9 1003391 10.1371/journal.ppat.1003391 23785279
108. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W, Initial report of a randomised double-blind placebo-controlled trial. Lancet 1981 2 8243 388 393
109. Viral hepatitis, type B (MS-2 strain). Studies on active immunization. Krugman S, Giles JP, Hammond J, JAMA 1971 217 41 45 10.1001/jama.1971. 03190010023005 4996665
110. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Purcell RH, Gerin JL, Am J Med Sci 1975 270 395 399 10.1097/00000441-197509000-00024 828832
111. Immunisation against hepatitis B in man. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P, Lancet 1976 1 7974 1367 1370 59012
112. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A, N Engl J Med 1980 303 833 841 10.1056/NEJM198010093031501 6997738 (Pubitemid 10014927)
113. Partial amino acid sequence of two major component polypeptides of hepatitis B surface antigen. Peterson DL, Roberts IM, Vyas GN, Proc Natl Acad Sci USA 1977 74 1530 1534 10.1073/pnas.74.4.1530 266193 (Pubitemid 8086189)
114. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD, Nature 1982 298 347 350 10.1038/298347a0 7045698 (Pubitemid 12044287)
115. Expression of hepatitis B surface antigen in yeast. Harford N, Cabezon T, Crabeel M, Simoen E, Rutgers A, De Wilde M, Dev Biol Stand 1983 54 125 130 6653884
116. Human hepatitis B vaccine from recombinant yeast. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR, Nature 1984 307 178 180 10.1038/307178a0 6318124 (Pubitemid 14132908)
117. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A, JAMA 1989 261 3278 3281 10.1001/jama.1989.03420220092033 2523981 (Pubitemid 19143550)
118. Viral hepatitis: global goals for vaccination. Lavanchy D, J Clin Virol 2012 55 296 302 10.1016/j.jcv.2012.08.022 22999800
119. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS, Taiwan Hepatoma Study Group, J Natl Cancer Inst 2009 101 1348 1355 10.1093/jnci/djp288 19759364
120. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH, J Infect Dis 2012 205 757 762 10.1093/infdis/jir852 22262790
121. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet J-M, J Viral Hepat 2011 18 369 375 10.1111/j.1365-2893.2010.01312.x 20384962
122. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Coates T, Wilson R, Patrick G, André F, Watson V, Clin Ther 2001 23 392 403 10.1016/S0149-2918(01)80044-8 11318074 (Pubitemid 32328745)
123. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Wolters B, Junge U, Dziuba S, Roggendorf M, Vaccine. 2003 21 3623 3628 10.1016/S0264-410X(03)00399-2 12922091 (Pubitemid 37338186)
124. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ, J Infect Dis 2010 201 1192 1200 10.1086/651378 20210630
125. Nucleic acid testing to detect HBV infection in blood donors. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain J-P, Gerlich W, New Engl J Med 2011 364 236 247 10.1056/NEJMoa1007644 21247314
126. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. Feeney SA, McCaughey C, Watt AP, El Agnaf MR, McDougal N, Morris K, Wend UC, Gerlich WH, Coyle PV, J Med Virol 2013 85 597 601 10.1002/jmv.23513 23359331
127. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D, J Hepatol 2011 55 29 37 10.1016/j.jhep.2010.10.019 21145866
128. Toward elimination and eradication of hepatitis B. Chen D-S, J Gastroenterol Hepatol 2010 25 11 25
129. Recombinant hepatitis B triple antigen vaccine: Hepacare. Zuckerman JN, Zuckerman AJ, Expert Rev Vaccines 2002 1 141 144 10.1586/14760584.1.2.141 12901552 (Pubitemid 36686863)
130. Hepatitis B, vaccines. Shouval D, J Hepatol 2003 39 Suppl 1 70 S76 14708681
131. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H, Vaccine 2006 24 2781 2789 10.1016/j.vaccine.2006.01.007 16455169
132. Recombinant Semliki forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies. Niedre-Otomere B, Bogdanova A, Skrastina D, Zajakina A, Bruvere R, Ose V, Gerlich WH, Garoff H, Pumpens P, Glebe D, Kozlovska T, J Viral Hepatitis 2012 19 664 673 10.1111/j.1365-2893.2012.01594.x